Blood-based test may provide a convenient and effective option for CRC screening in the average-risk U.S. population
Blood-based test may provide a convenient and effective option for CRC screening in the average-risk U.S. population
Everolimus plus lanreotide might be a new standard treatment in the first-line setting for grade 1/2 GEP-NETs
Gemcitabine/nab-paclitaxel compared with 5-fluorouracil/leucovorin/liposomal irinotecan shows similar results in older patients
Prostate cancer
Rectal cancer
Breast cancer
Radiobiology of hypofractionation
Physics of hypofractionated radiotherapy
Enhancing patient safety: The critical role of pharmacovigilance in oncology
AI in multiple myeloma: Recent findings and opportunities
Isatuximab survival benefit over VRd in transplant-ineligible newly diagnosed multiple myeloma
Optimising immunoglobulin dosing can enhance patient outcomes in multiple myeloma